Construction of a Platform for the Development of Pharmaceutical and Medical Applications Using Transgenic Silkworms

DOI Web Site Web Site PubMed 1 Citations 17 References
  • Sezutsu Hideki
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization Graduate School of Frontier Sciences, The University of Tokyo
  • Sumitani Megumi
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization
  • Kondo Mari
    Graduate School of Frontier Sciences, The University of Tokyo
  • Kobayashi Isao
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization
  • Takasu Yoko
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization
  • Suzuki Takao
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization
  • Yonemura Naoyuki
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization
  • Iizuka Tetsuya
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization
  • Uchino Keiro
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization
  • Tamura Toshiki
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization
  • Tsubota Takuya
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization
  • Tatematsu Ken-ichiro
    Institute of Agrobiological Sciences, National Agriculture and Food Research Organization

Bibliographic Information

Other Title
  • 遺伝子組換えカイコによる医薬品開発プラットフォームの構築
  • Symposium Review 遺伝子組換えカイコによる医薬品開発プラットフォームの構築
  • Symposium Review イデンシ クミカエ カイコ ニ ヨル イヤクヒン カイハツ プラットフォーム ノ コウチク

Search this article

Abstract

　We have been constructing a platform for the development of pharmaceutical and medical applications using the domesticated silkworm, Bombyx mori, as a new animal model for drug development and evaluation. Because silkworm larvae originally have the capacity to synthesize up to 0.5 g of silk proteins, genetically modified silkworms (transgenic silkworms) are expected to have high potential in the production of recombinant silks/proteins. An innovative method for generating transgenic silkworms was established in 2000, and ever since this epoch-defining technological development, longstanding efforts have succeeded in developing novel silks that enable the manufacture of new textile materials for regenerative medical uses. Furthermore, we have succeeded in developing a new system of recombinant protein production. This recombinant protein production system is currently capable of producing a maximum of approximately 15 mg recombinant protein per silkworm larva. Transgenic silkworms have also been shown to produce a wide variety of useful proteins, including antibodies and membrane proteins. Some of these recombinant proteins have been in commercial use since 2011. In addition, we have been developing transgenic silkworms as a novel animal model for testing medicines based on metabolic similarities between silkworms and mammals. These applications show the suitability and potential of transgenic silkworms for medical use. Here, we will describe the challenges faced in creating a transgenic silkworm-based platform for pharmaceutical and medical applications.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 138 (7), 863-874, 2018-07-01

    The Pharmaceutical Society of Japan

Citations (1)*help

See more

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top